Source: International Congress 2018 – New methods for diagnosing and treating lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Rademacher (Hannover, Germany), S. Konwert (Hannover, Germany), J. Fuge (Hannover, Germany), T. Welte (Hannover, Germany), F. Ringshausen (Hannover, Germany). Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition. 3265

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Biological determinants of sputum rheology in chronic airway diseases Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020 Late Breaking Abstract - Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Airway hyperresponsiveness in bronchiectasis Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 Late Breaking Abstract - A GATA3-specific DNAzyme attenuates sputum eosinophilia in COPD patients with eosinophilic airway inflammation Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Rituximab limits the progression of fibrosing mediastinitis Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives Year: 2019 Late Breaking Abstract - Benefits of a low-frequency airway clearance technology in non-CF patients with bronchiectasis Source: International Congress 2018 – Management of chronic cough and respiratory muscle dysfunction Year: 2018 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Late Breaking Abstract - Fully automated airway measurement correlates with radiological disease progression in Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Remote monitoring of respiratory patients Year: 2021 Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019